The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

(Updated) Osteoporosis drugs including oral bisphosphonates show efficacy and safety in the treatment of bone loss in patients with chronic kidney disease (CKD) in several observational studies.

Subsequent denosumab doses were associated with lower risks for hypocalcemia among patients with osteoporosis and chronic kidney disease . Magnitude of serum calcium decrease is smaller with ...

The intricate relationship between chronic kidney disease (CKD) and bone mineral density (BMD) is an area of burgeoning clinical and research interest. CKD is characterised by a progressive loss of ...

The use of antiresorptive drugs for tumor-related disorders and oral, but not injectable, corticosteroids were associated with an increased risk for osteonecrosis of the jaw among patients with ...

A new consensus paper provides an updated evaluation of reference bone turnover markers (BTMs) and newer markers in the diagnosis and management of osteoporosis. The paper, titled "Update on the Role ...

Nephrologists should take action to address CKD-associated osteoporosis to improve both short and long-term clinical outcomes. Attention should be given to vertebral fractures given their strong ...

A coalition of leading inTernational experts in nephrology, bone health, and musculoskeletal disease has released the first comprehensive consensus statement on the management of vertebral fractures ...